{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:17:38Z","timestamp":1760552258488,"version":"3.44.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.annder.2025.103390","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:36:54Z","timestamp":1748965014000},"page":"103390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Angiolymphoid hyperplasia with eosinophilia treated with dupilumab in a biologic-na\u00efve patient"],"prefix":"10.1016","volume":"152","author":[{"given":"M.F.","family":"Ortiz-Nu\u00f1o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Esquivel-Valerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Garc\u00eda-Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.","family":"Galarza-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Cardenas-de la Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2025.103390_b0005","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.annder.2025.103390_b0010","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.19116","article-title":"Angiolymphoid hyperplasia with eosinophilia infiltrated by GATA3+ Th2 cells responding to dupilumab","author":"Seidl","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annder.2025.103390_b0015","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/jamadermatol.2022.1969","article-title":"Use of dupilumab and eosinophil targeted therapy in treating angiolymphoid hyperplasia with eosinophilia","volume":"158","author":"Franke","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2025.103390_b0020","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamadermatol.2021.2732","article-title":"Role of eosinophils in angiolymphoid hyperplasia with eosinophilia","volume":"157","author":"Gr\u00fcnewald","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annder.2025.103390_b0025","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/j.1365-2133.2004.06239.x","article-title":"Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab)","volume":"151","author":"Braun-Falco","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2025.103390_b0030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2015.10.011","article-title":"Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): A systematic review","volume":"74","author":"Adler","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963825000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:04:15Z","timestamp":1757628255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963825000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0151963825000493"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2025.103390","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiolymphoid hyperplasia with eosinophilia treated with dupilumab in a biologic-na\u00efve patient","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2025.103390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103390"}}